Cargando…

Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance

PURPOSE: The safety of active surveillance (AS) in favorable intermediate-risk (FIR) prostate cancer (PCa) remains uncertain. To provide guidance on clinical decision-making, we examined long-term and pathological outcomes of low-risk and intermediate-risk PCa patients after radical prostatectomy (R...

Descripción completa

Detalles Bibliográficos
Autores principales: Meissner, Valentin H., Woll, Mira, Ankerst, Donna P., Schiele, Stefan, Gschwend, Jürgen E., Herkommer, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521579/
https://www.ncbi.nlm.nih.gov/pubmed/33973043
http://dx.doi.org/10.1007/s00345-021-03717-2
_version_ 1784584928188432384
author Meissner, Valentin H.
Woll, Mira
Ankerst, Donna P.
Schiele, Stefan
Gschwend, Jürgen E.
Herkommer, Kathleen
author_facet Meissner, Valentin H.
Woll, Mira
Ankerst, Donna P.
Schiele, Stefan
Gschwend, Jürgen E.
Herkommer, Kathleen
author_sort Meissner, Valentin H.
collection PubMed
description PURPOSE: The safety of active surveillance (AS) in favorable intermediate-risk (FIR) prostate cancer (PCa) remains uncertain. To provide guidance on clinical decision-making, we examined long-term and pathological outcomes of low-risk and intermediate-risk PCa patients after radical prostatectomy (RP). METHODS: The study involved 5693 patients diagnosed between 1994 and 2019 with low-risk, FIR, and unfavorable intermediate-risk (UIR) PCa (stratification according to the AUA guidelines) who underwent RP. Pathological outcomes were compared, and Kaplan–Meier analysis determined biochemical recurrence-free survival (BRFS) and cancer-specific survival (CSS) at 5, 10, 15, and 20 years. Multiple Cox regression was used to simultaneously control for relevant confounders. RESULTS: Those at FIR had higher rates of upgrading and upstaging (12.8% vs. 7.2%, p < 0.001; 19.8% vs. 12.0%, p < 0.001) as well as pathological tumor and node stage (≥ pT3a: 18.8% vs. 11.6%, p < 0.001; pN1: 2.7% vs. 0.8%, p > 0.001) compared to patients at low risk. The 20-year BRFS was 69%, 65%, and 44% and the 20-year CSS was 98%, 95%, and 89% in low-risk, FIR, and UIR patients. On multiple Cox regression, FIR was not associated with a worse BRFS (HR 1.07, CI 0.87–1.32), UIR was associated with a worse BRFS (HR 1.49, CI 1.20–1.85). CONCLUSION: Patients at FIR had only slightly worse pathological and long-term outcomes compared to patients at low risk, whereas the difference compared to patients at UIR was large. This emphasizes AS in these patients as a possible treatment strategy in well-counseled patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-021-03717-2.
format Online
Article
Text
id pubmed-8521579
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85215792021-10-22 Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance Meissner, Valentin H. Woll, Mira Ankerst, Donna P. Schiele, Stefan Gschwend, Jürgen E. Herkommer, Kathleen World J Urol Original Article PURPOSE: The safety of active surveillance (AS) in favorable intermediate-risk (FIR) prostate cancer (PCa) remains uncertain. To provide guidance on clinical decision-making, we examined long-term and pathological outcomes of low-risk and intermediate-risk PCa patients after radical prostatectomy (RP). METHODS: The study involved 5693 patients diagnosed between 1994 and 2019 with low-risk, FIR, and unfavorable intermediate-risk (UIR) PCa (stratification according to the AUA guidelines) who underwent RP. Pathological outcomes were compared, and Kaplan–Meier analysis determined biochemical recurrence-free survival (BRFS) and cancer-specific survival (CSS) at 5, 10, 15, and 20 years. Multiple Cox regression was used to simultaneously control for relevant confounders. RESULTS: Those at FIR had higher rates of upgrading and upstaging (12.8% vs. 7.2%, p < 0.001; 19.8% vs. 12.0%, p < 0.001) as well as pathological tumor and node stage (≥ pT3a: 18.8% vs. 11.6%, p < 0.001; pN1: 2.7% vs. 0.8%, p > 0.001) compared to patients at low risk. The 20-year BRFS was 69%, 65%, and 44% and the 20-year CSS was 98%, 95%, and 89% in low-risk, FIR, and UIR patients. On multiple Cox regression, FIR was not associated with a worse BRFS (HR 1.07, CI 0.87–1.32), UIR was associated with a worse BRFS (HR 1.49, CI 1.20–1.85). CONCLUSION: Patients at FIR had only slightly worse pathological and long-term outcomes compared to patients at low risk, whereas the difference compared to patients at UIR was large. This emphasizes AS in these patients as a possible treatment strategy in well-counseled patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00345-021-03717-2. Springer Berlin Heidelberg 2021-05-10 2021 /pmc/articles/PMC8521579/ /pubmed/33973043 http://dx.doi.org/10.1007/s00345-021-03717-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Meissner, Valentin H.
Woll, Mira
Ankerst, Donna P.
Schiele, Stefan
Gschwend, Jürgen E.
Herkommer, Kathleen
Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
title Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
title_full Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
title_fullStr Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
title_full_unstemmed Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
title_short Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
title_sort long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521579/
https://www.ncbi.nlm.nih.gov/pubmed/33973043
http://dx.doi.org/10.1007/s00345-021-03717-2
work_keys_str_mv AT meissnervalentinh longtermandpathologicaloutcomesoflowandintermediateriskprostatecancerafterradicalprostatectomyimplicationsforactivesurveillance
AT wollmira longtermandpathologicaloutcomesoflowandintermediateriskprostatecancerafterradicalprostatectomyimplicationsforactivesurveillance
AT ankerstdonnap longtermandpathologicaloutcomesoflowandintermediateriskprostatecancerafterradicalprostatectomyimplicationsforactivesurveillance
AT schielestefan longtermandpathologicaloutcomesoflowandintermediateriskprostatecancerafterradicalprostatectomyimplicationsforactivesurveillance
AT gschwendjurgene longtermandpathologicaloutcomesoflowandintermediateriskprostatecancerafterradicalprostatectomyimplicationsforactivesurveillance
AT herkommerkathleen longtermandpathologicaloutcomesoflowandintermediateriskprostatecancerafterradicalprostatectomyimplicationsforactivesurveillance